Volume 3 | November 2, 2022 | View in Browser
There is no I in oSTeosARcoma, but there is definitely a huge team of STARs that light the way for our community! Joel Madden solved his way to $198,250 for MIB Agents on Celebrity Wheel of Fortune to support more osteosarcoma research, education, and patient programs.We welcome a new Board member who brings 20 years of industry experience to our steering team. OutSmarting Osteosarcoma 2020 recipient and star Dr. Livingston will host MIB Agents Family Funds at MD Anderson Cancer Center inHouston for an update on his research. Our OutSmarting Osteosarcoma 2023 grant application will open on 11/3/22. Because of our phenomenal Family Funds and donors, we expect to fund multiple grants again this year! Apply for a grant and join our all-star research team and #CauseACure with us!
Joel Madden crushes Celebrity Wheel of Fortune to win $198,250 for MIB Agents to support osteosarcoma research and patient programs. Watch the episode and thank Joel for raising awareness about osteosarcoma @JoelMadden
MIB Agents will be in Houston on November 30th! Come mingle with us at the Blossom Hotel from 5-7pm. Everyone in the osteosarcoma community is invited - doctors, researchers, patients, and caregivers. If you are near the Houston area, we would love to see you!
Dr. Beth Odeh-Frikert Joins the MIB Agents Board
With over 20 years of industry experience from Genentech and Roche, Beth adds valuable perspective and insight to our MIB Agents Board. As the Head of Global Alliance and Asset Management, Pharma Partnering at Genentech, Beth heads the group that builds partnerships and fosters collaborative relationships with world-class leaders in the pharmaceutical and biotechnology industries. Her collaborative focus perfectly aligns with what MIB Agents is all about!
Tyler was diagnosed with osteosarcoma in his right humerus in December 2012. After completing chemotherapy, he endured multiple surgeries. Tyler participated in the PARP-inhibitor and the WEE1 inhibitor clinical trials at UCSF with the wish that “If it can save me, that would be great and hopefully it can help another kid.” Tyler's family started this fund knowing that finding better treatments for osteosarcoma is something Tyler would have pursued.
Dr. Andy Livingston, MD, MS, is a clinician and researcher in Sarcoma Medical Oncology at MD Anderson Cancer Center and holds a joint appointment in Pediatric Oncology. With a particular interest in the care of teens and young adults with cancer, he is Co-director of the MD Anderson Adolescent and Young Adult (AYA) oncology program. His clinical and translational research is focused on developing new treatment strategies for patients with osteosarcoma and other bone sarcomas.
An MIB Agents Family Fund® Exclusive: All MIB Agents Family Funds® are invited to join us on December 1st in Houston for an update from Dr. Livingston, recipient of the 2020 OutSmarting Osteosarcoma grant. The visit will include anexclusive peek inside the Haymaker Lab at the MD Anderson Cancer Center. A very limited number of spots are available on a first-come, first-served basis. Register or email email@example.com for more info.
If you have a job posting and you would like it included here, please email firstname.lastname@example.org.
A virtual tumor review board for osteosarcoma, TURBO is open to clinicians or researchers with an interest in osteosarcoma. Patients and families are welcome to ask their oncologists to present a case on their behalf. Join TURBO to request an invite or submit a case.Next meeting: November 9th at 5pm ET.
When an OsteoWarrior transitions to hospice care, MIB Agents provides an experience or an item of comfort and entertainment. To be eligible, patients must be diagnosed with osteosarcoma, be 22 years old or younger, and have exhausted all curative treatment options. MIB Agents has fulfilled 36 missions to date.
MIB Agents is offering a special Healing Hearts During the Holidays workshops at two times on November 21st: 7pm ET and 7pm PT. Led by grief counselor Lori Krause, these workshops are free of charge to bereaved parents.
Collaboration among the scientific and patient communities is a key hallmark of MIB Agents. MIB Agents OutSmarting Osteosarcoma grants are supported by MIB Agents Family Funds, osteosarcoma patients, and families who raise funds in honor of an OsteoWarrior or OsteoAngel. Their dedication to Making It Better and fostering collaboration and education in the scientific community makes every MIB Agents award incredibly meaningful.
2023 funding mechanisms include a $100,000 one-year grant and a $50,000 one-year grant for young investigators.
Begun in 2017, OutSmarting Osteosarcoma has supported eleven investigators and awarded $950,000 to support osteosarcoma research. We expect to award multiple grants in 2023.
SARC is seeking CDA applications from early-stage physicians or scientists conducting sarcoma research in the US or Canada; qualified candidates will be within five years of their first faculty appointment with a rank of Instructor or Assistant Professor OR in the final year of clinical fellowship or postdoctoral fellowship. SARC Career Development Awards are awarded in the amount of $100,000, with a second year of funding contingent on satisfactory progress and availability of funds. LOI Submission Deadline: December 16, 2022
The patients and parents group in the FOSTER (Fight OSteosarcoma Through European Research) consortium are undertaking the first-ever global survey for bone sarcoma patients. Take the survey to have your voice heard and share your experiences and research priorities.
The survey is open to all global bone sarcoma patients, survivors, and caregivers.
Access the MIB Agents clinical trials search powered by Antidote to find a clinical trial for osteosarcoma in 60 seconds.
If you have a trial that is currently enrolling osteosarcoma patients and you would like it included here, please email email@example.com.
BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. Their drug, Voraxaze, is for high-dose methotrexate toxicity.Learn more about methotrexate.
Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Their osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.